Genomics

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

Genomic Testing Cooperative opens a Houston lab, leveraging the city's elite oncology ecosystem to expand its unique cooperative model for cancer testing.

A NY startup is using quantum computing and AI to fight aging at its source. Can Allosteric Bioscience's high-tech approach unlock a longer, healthier life?

An AI firm known for fighting cancer is now partnering with Unilever, signaling a new era of biologically personalized consumer products and new ethical questions.

Zoetis is acquiring Neogen's genomics unit for $160M, a strategic move set to accelerate data-driven innovation in livestock and companion animal care.

With star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.

Nabsys's electronic genome mapping reveals how rogue genetic elements damage our DNA, opening new frontiers in understanding cancer and neurodegeneration.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

Acquiring Complete Genomics, Swiss Rockets unveils its CoolMPS 600, a bid to democratize long-read sequencing with breakthrough cost and accuracy.

New England Biolabs is launching next-gen sample prep tools, targeting long-read sequencing, RNA bias, and clinical epigenetics to accelerate discovery.

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

Watchmaker Genomics is repurposing CRISPR, not for editing genes, but to make DNA sequencing faster, cheaper, and more reliable than ever before.

A genomic test identifies which breast cancer patients truly benefit from extended hormone therapy, a major step toward personalized long-term care.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

Katherine Stueland’s honor underscores a major shift in healthcare, as genomic screening and AI promise to end the diagnostic odyssey for rare diseases.

UCLA's Dr. Donald Kohn joins the Jeffrey Modell Foundation to discuss revolutionary gene therapies offering new hope for Primary Immunodeficiency patients.